Effect of Low-fat Diet on the Pharmacokinetics of Pyrotinib in Healthy Participants
A Randomized, Open, Single-dose, Two-cycle, Double-sequence, Crossover Study to Investigate the Effects of a Low-fat Diet On the Pharmacokinetics of Healthy Chinese Adult Participants After Oral Administration of Pyrotinib Maleate Tablets
The primary objective of the study is to evaluate the effect of low-fat diet on pharmacokinetics of healthy Chinese adult participants after oral administration of pyrotinib maleate tablets.
The secondary objective of the study is to evaluate the safety of single dose of pyrotinib orally in healthy participants.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Contact
Study Contact
- Name: Yuya Wang, Ph.D.
- Phone Number: 86-13918749176
- Email: wangyuya@hrglobe.cn
Study Contact Backup
- Name: Chao Lu, M.M.
- Phone Number: 86-18005693201
- Email: 765385306@qq.com
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Sign the informed consent before the trial, and fully understand the trial content, process and possible adverse reactions;
- Ability to complete the study as required by the protocol;
- Healthy male or female subjects aged 18 to 45 (including 18 and 45) at the date of signing the informed consent;
- Have no fertility plan and agree to adopt effective contraceptive measures within 2 weeks before the first study drug administration and up to 3 months after the last study drug administration. Negative pregnancy test for women of child-bearing age before the first study drug administration;
- Male body weight ≥ 50kg, female body weight ≥ 45kg, and body mass index (BMI) within the range of 19 ~ 26 kg/m^2 (including 19 and 26);
- During screening period, the comprehensive physical examination (vital signs and physical examination), routine laboratory examination (blood routine, urine routine, blood biochemistry, coagulation,etc), 12-lead electrocardiogram (ECG), chest X-ray, cardiac ultrasound, B ultrasound and other examination results must be within the normal range, or judged to be "no clinical significance (NCS)" if beyond the normal range;
Exclusion Criteria:
- Blood donation within 3 months before the first drug administration and blood loss greater than 400 mL, or receiving blood transfusion;
- Allergic constitution, including those with severe drug allergies or a history of drug allergies, or known allergy to the research drug;
- History of drug use, or drug abuse screening positive; history of drug abuse within the past five years or have used drugs 3 months before the test;
- Alcoholic or often drinkers (the average drinking amount is more than 14 units a week: 1 unit= 285 ml beer or 45 ml spirits or 100 ml wine; ≥5 cigarettes per day) and can't quit smoking and alcohol during the study; alcohol test positive;
- The 12-lead ECG with female QTcF > 470ms or male QTcF > 450ms;
- Left ventricular ejection fraction (LVEF) <50% by echocardiography;
- A clear medical history of important primary organ diseases such as nervous system, cardiovascular system, urinary system, digestive system, respiratory system, metabolism and musculoskeletal system.
- Those who have undergone any surgery within 6 months before screening;
- Those who have taken hepatotoxic drugs (such as dapsone, erythromycin, fluconazole, ketoconazole, rifampicin) for a long time within the 6 months before screening;
- Those who have taken any research drugs within 3 months before the first drug administration;
- Use any drugs that changes liver enzyme activity within 4 weeks before the first drug administration;
- Use any prescription or over-the-counter drug, any vitamin product, health supplement or herbal medicine within 2 weeks prior to first drug administration;
- Abnormal clinical laboratory tests and clinical significance judged by the investigator or other clinical findings showing the following diseases, including but not limited to gastrointestinal tract, kidney, liver, nerve, blood, endocrine, tumor, lung, immune, mental or cardiovascular and cerebrovascular diseases;
- HCV antibody positive, HIV antibody positive, HBsAg positive, and syphilis antibody positive;
- Consumption of grapefruit or grapefruit-containing products, foods or beverages containing caffeine, xanthine, or alcohol within 48 hours before the first drug administration; strenuous exercise or other factors that effect on drug absorption, distribution, metabolism and excretion;
- Have special requirements on diet and cannot comply with the diet and corresponding regulations provided by the test;
- History of dizzy needles or blood dizziness; difficulty in venous blood collection or inability to tolerate venipuncture;
- lactating women;
- Other factors that are not suitable for participating in the study, as judged by the investigator.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: A
|
pyrotinib maleate administration in fasted condition in period 1, pyrotinib maleate administration after low-fat diet in period 2
|
|
Experimental: B
|
pyrotinib maleate administration after low-fat diet in period 1, pyrotinib maleate administration in fasted condition in period 2
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Pharmacokinetics parameter: Cmax of pyrotinib
Time Frame: through study completion, an average of 28 days
|
Peak Plasma Concentration (Cmax) of pyrotinib
|
through study completion, an average of 28 days
|
|
Pharmacokinetics parameter: AUC of pyrotinib
Time Frame: through study completion, an average of 28 days
|
Area under the plasma concentration versus time curve (AUC) of pyrotinib
|
through study completion, an average of 28 days
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Pharmacokinetics parameter: Tmax of pyrotinib
Time Frame: through study completion, an average of 28 days
|
Time of maximum observed concentration (Tmax) of pyrotinib
|
through study completion, an average of 28 days
|
|
Pharmacokinetics parameter: T1/2 of pyrotinib
Time Frame: through study completion, an average of 28 days
|
Half time (T1/2) of pyrotinib
|
through study completion, an average of 28 days
|
|
Pharmacokinetics parameter: CL/F of pyrotinib
Time Frame: through study completion, an average of 28 days
|
Total body clearance for extravascular administration (CL/F) of pyrotinib
|
through study completion, an average of 28 days
|
|
Pharmacokinetics parameter: Vz/F of pyrotinib
Time Frame: through study completion, an average of 28 days
|
Volume of distribution (Vz/F) of pyrotinib
|
through study completion, an average of 28 days
|
|
Number of participants with treatment-related adverse events as assessed by CTCAE v5.0
Time Frame: through study completion, an average of 28 days
|
An adverse event is any untoward medical occurrence in a patient or clinical study participant
|
through study completion, an average of 28 days
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Anticipated)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- BLTN-If
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.